A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren

Trial Profile

A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 04 Oct 2016 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 04 Oct 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
    • 04 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top